Drug intelligence / Profile preview

211At-ofatumumab-B10

Development stage: Preclinical
Lead developer: Fred Hutchinson Cancer Center
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

211At-ofatumumab-B10 is an experimental radioimmunotherapy consisting of the anti-CD20 monoclonal antibody ofatumumab radiolabeled with the alpha-emitting radioisotope astatine-211 (211At) via the amine-reactive labeling agent B10-NCS. Developed by researchers at the Fred Hutchinson Cancer Center, this construct is designed to deliver high-energy alpha radiation directly to target cells, inducing lethal double-stranded DNA breaks within a very short range (50-90 μm). In the context of multiple myeloma research, 211At-ofatumumab-B10 has been utilized as a non-binding isotype control to evaluate the specificity and therapeutic efficacy of BCMA-targeted alpha-emitter therapies, such as 211At-BCMA-B10, in mouse xenograft models.

Other names: astatine-211-labeled ofatumumabastatine211-labeled ofatumumabastatine 211-labeled ofatumumab211At-ofatumumab

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)C1Q (Complement C1q)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on 211At-ofatumumab-B10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 211At-ofatumumab-B10.

Explore the full profile